$PROK News

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

ProKidney Appoints Kenneth Locke as Chief Technical Officer

HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate

ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel

What Makes ProKidney Corp. (PROK) So Attractive

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate

Prokidney Updates Phase 3 REGEN-006 Trial Enrollment Of ~470 Subjects

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript